NCT06727370Recruiting
Cognitive Screening in Lung Cancer Patients
Source: ClinicalTrials.gov · Last updated 10 Dec 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to investigate the occurrence of cancer and adjuvant therapy-related cognitive impairment in patients with both NSCLC and SCLC. The primary endpoint measure will be the presence of cognitive impairment during the first year after enrollment through the administration of a comprehensive neuropsychological assessment.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 21 Nov 2024
- Start date
- 10 Jan 2024
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- European Institute of Oncology
- Diseases
- Lung cancer
- NCT number
- NCT06727370
What you commit to
- Study type: Observational
- Planned participants: 200
- From 10 Jan 2024 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with concomitant neurological or psychiatric disorders.
- Patients undergoing brain radiotherapy
- Previous diagnosis of lung cancer
Age
- Age ≥ 70
Other
- Presence of brain metastases
Who the study is looking for
- Small-cell and non-small-cell lung cancer (stage I, II, III, IV)
- Age ≥ 18 years
- Patients able to speak and read the local language(s) fluently
- Acceptance and signature of informed consent
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Istituto Europeo di Oncologia Coordinator of this site? Confirm its status | Milan | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.